Clinical Trials Directory

Trials / Completed

CompletedNCT06151379

Muscle Parameters and Pathological Response in Breast Cancer Patients

The Relation Between the Initial Value of the Skeletal Mass Index and Pathological Response

Status
Completed
Phase
Study type
Observational
Enrollment
69 (actual)
Sponsor
Acıbadem Atunizade Hospital · Academic / Other
Sex
Female
Age
29 Years – 72 Years
Healthy volunteers

Summary

The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.

Detailed description

In patients with operable breast cancer (BC) receiving neoadjuvant chemotherapy (NAC), the pathological response rate was found to be related to body composition. The success of complete pathologic response (pCR) is a known prognostic factor in BC patients treated with NAC. The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.

Conditions

Interventions

TypeNameDescription
OTHERNeoadjuvant therapyTo measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.

Timeline

Start date
2023-03-01
Primary completion
2023-09-30
Completion
2023-10-20
First posted
2023-11-30
Last updated
2023-11-30

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06151379. Inclusion in this directory is not an endorsement.

Muscle Parameters and Pathological Response in Breast Cancer Patients (NCT06151379) · Clinical Trials Directory